Price Alert

Protagonist Therapeutics ... (PTGX)

NASDAQ: PTGX · Real-Time Price · USD

56.13

0.06 (0.11%)

At close: Aug 18, 2025, 3:59 PM

55.91

-0.39%

Pre-market: Aug 19, 2025, 04:33 AM EDT

0.11% (1D)

Bid	54.67
Market Cap	3.49B
Revenue (ttm)	203.63M
Net Income (ttm)	52.04M
EPS (ttm)	0.73
PE Ratio (ttm)	76.89
Forward PE	-283.67
Analyst	Buy

Ask	58
Volume	379,650
Avg. Volume (20D)	807,885
Open	56.64
Previous Close	56.07
Day's Range	55.51 - 57.99
52-Week Range	33.31 - 60.60
Beta	2.33

About PTGX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PTGX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PTGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Protagonist Therapeutics Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 months ago

+45.89%

Protagonist Therapeutics shares are trading higher... Unlock content with Pro Subscription

5 months ago

+2.42%

Protagonist Therapeutics shares are trading higher after the company announced its Polycythemia Vera Phase 3 study with Takeda met all its key goals.

News

1 week ago · fool.com

Protagonist (PTGX) Q2 Revenue Falls 26%

1 week ago · zacks.com

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.

1 week ago · accessnewswire.com

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of ico...

1 month ago · accessnewswire.com

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the...

1 month ago · seekingalpha.com

Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case

Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...

2 months ago · businesswire.com

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase...

2 months ago · accessnewswire.com

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.